Nutrition during GLP-1 therapy isn't an "extra"; it's a standard part of modern obesity care. Three recent studies show — in plain language — what happens and what helps.
— Butsch et al., 2025
Obesity Pillars · n = 461,382
1 in 5 GLP-1 users develops a diagnosed nutritional deficiency within a year.
In a large real-world analysis of nearly half a million US adults newly starting a GLP-1 medication (mostly semaglutide and tirzepatide), 22.4% had a new diagnosed nutritional deficiency within 12 months. Vitamin D was the most common (13.6% at one year), followed by other B-vitamins (2.6%) and iron-deficiency anaemia (3.2%). About 3% received a "muscle loss" diagnosis.
The authors conclude that structured nutritional screening during GLP-1 therapy is valuable — especially because many deficiencies go unnoticed without blood work.
What this means
Deficiencies aren't a fringe issue: roughly 1 in 5 GLP-1 users develops one — often without immediate symptoms. A good multivitamin covers most of this risk.
— Locatelli et al., 2024
Diabetes Care · narrative review
About 10% of the body weight you lose is muscle mass.
This review pooled data from major GLP-1 trials (including STEP-1 for semaglutide and SURMOUNT-1 for tirzepatide). The conclusion: of total weight loss with incretin medications, roughly 10% (~6 kg) is lean body mass — primarily muscle. That's comparable to what the body loses in ten years of ageing.
The good news: structured resistance training for more than 10 weeks can rebuild around 3 kg of lean mass and increase muscle strength by ~25%. The authors recommend making resistance training a standard part of GLP-1 therapy — not just to preserve muscle, but also to reduce weight regain after stopping medication.
What this means
It's not just "eat less, lose weight". A significant portion of the loss is muscle, with implications for energy, strength, and the risk of regain. Protein-rich nutrition and resistance training belong with the medication.
— Mozaffarian et al., 2025
Am J Clin Nutr · joint advisory
Four leading medical societies: nutrition belongs at the core of GLP-1 care.
A joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society — four of the most authoritative organisations in this field. The expert panel (led by Mozaffarian of Tufts University) reviewed the literature and set out concrete priorities.
Their key recommendations for patients on GLP-1s: 1.2 to 1.6 grams of protein per kg of body weight per day during active weight loss (versus the standard 0.8 g/kg), eating protein-rich foods first in a meal to ensure adequate intake, structured resistance training to preserve muscle and bone, and attention to micronutrients. In the STEP-1 trial, 38% of total weight loss was lean body mass.
What this means
The international consensus is clear: GLP-1 alone isn't enough — nutrition, protein, and exercise make the difference between "short-term weight loss" and "lasting health gain".